Anders Ekblom

Chairman of the Board
  • Board member since: 2017
  • Independent in relation to the Company and its management: Yes
  • Independent in relation to major shareholders: Yes
  • Holdings in Alligator: 367,696 shares, 100,000 warrants in program TO 2022/2025 II, 240,000 warrants in program TO 2023/2026 II and 160,000 warrants in program TO 2024/2027 II.
  • Other current positions: Chairman of Atrogi AB, Elypta AB and Xspray Pharma AB. Board member of AnaMar AB, Flerie Invest AB and Mereo BioPharma Group plc

Anders Ekblom – born 1954, Chairman since 2021 and Board member since 2017 – is a physician, board certified in anaesthesia and intensive care, dentist and Associate Professor in physiology at the Karolinska Institute. Anders Ekblom has extensive experience from the biopharmaceutical industry globally, including being EVP Global Medicines Development at AstraZeneca and CEO and president of AstraZeneca AB Sweden.

Updated 2024-05-21